<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106077">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156362</url>
  </required_header>
  <id_info>
    <org_study_id>2011.665</org_study_id>
    <nct_id>NCT02156362</nct_id>
  </id_info>
  <brief_title>Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)</brief_title>
  <official_title>Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is generally estimated that 5 % of patients with thyroid cancer will develop distant
      metastases, and most of them had an advanced stage of the disease at presentation. Thirty
      per cent of them are resistant to radio iodine therapy and are called &quot;refractory&quot;. Their
      long term survival is estimated to be less than 10 %.

      The objective of this study is to identify the factors associated with poor outcome in a
      cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and
      medullary thyroid carcinomas were excluded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Rate of Thyroid cancer evolving to refractory stage</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>follow up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>follow up visit</intervention_name>
    <description>At least 1 follow up visit per year will be done and an additional visit if needed.</description>
    <arm_group_label>follow up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman ≥ 18 years.

          -  Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly
             differentiated carcinoma).

          -  TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.

          -  Patient after post operative radioiodine therapy.

        Exclusion Criteria:

          -  Patient who can not be followed during the protocol.

          -  Patient who does not consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire BOURNAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon- Centre de Médecine Nucléaire Groupement hospitalier est, 59 boulevard Pinel, 69677 Bron cedex</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire BOURNAUD, MD</last_name>
    <phone>+33472356999</phone>
    <email>claire.bournaud-salinas@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Françoise BORSON-CHAZOT, PHD,MD</last_name>
    <phone>+33472119319</phone>
    <email>francoise.borson-chazot@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel</name>
      <address>
        <city>Bron cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire BOURNAUD, MD</last_name>
      <phone>+33472356999</phone>
      <email>claire.bournaud-salinas@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Françoise BORSON-CHAZOT, PHD,MD</last_name>
      <phone>+33472119319</phone>
      <email>francoise.borson-chazot@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Claire BOURNAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid carcinoma</keyword>
  <keyword>predictive factors</keyword>
  <keyword>refractory</keyword>
  <keyword>Differentiated</keyword>
  <keyword>follicular origin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
